We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J’s Risperdal Consta Approved for Bipolar I
J&J’s Risperdal Consta Approved for Bipolar I
May 22, 2009
The FDA has approved Johnson & Johnson (J&J) subsidiary Ortho-McNeil-Janssen Pharmaceuticals’ sNDA to expand the indication for its antipsychotic Risperdal Consta as both mono-therapy and adjunctive therapy to lithium or valproate to treat bipolar I disorder.